Prestige Consumer Healthcare (NYSE:PBH) Price Target Cut to $72.00 by Analysts at Canaccord Genuity Group

Prestige Consumer Healthcare (NYSE:PBH) had its target price cut by analysts at Canaccord Genuity Group from $86.00 to $72.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 53.40% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Jefferies Financial Group reduced their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Price Performance

PBH stock traded up $1.01 during midday trading on Friday, reaching $46.94. 1,149,580 shares of the stock were exchanged, compared to its average volume of 505,620. The stock has a market capitalization of $2.22 billion, a PE ratio of 11.99, a P/E/G ratio of 1.55 and a beta of 0.40. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $89.37. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The company has a fifty day moving average price of $58.32 and a 200 day moving average price of $61.49.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to the consensus estimate of $291.99 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.62%. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts expect that Prestige Consumer Healthcare will post 4.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UMB Bank n.a. grew its position in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd bought a new position in Prestige Consumer Healthcare in the 4th quarter worth about $29,000. First Horizon Corp purchased a new position in Prestige Consumer Healthcare during the 3rd quarter valued at about $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).